Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Vivos Therapeutics (VVOS) Non-Current Receivables (2019 - 2021)

Vivos Therapeutics (VVOS) has disclosed Non-Current Receivables for 3 consecutive years, with $842290.0 as the latest value for Q3 2021.

  • On a quarterly basis, Non-Current Receivables changed N/A to $842290.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $842290.0, a N/A change, with the full-year FY2020 number at $811000.0, up 3.3% from a year prior.
  • Non-Current Receivables was $842290.0 for Q3 2021 at Vivos Therapeutics, roughly flat from $846214.0 in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $846214.0 in Q2 2021 to a low of $785061.0 in Q4 2019.
  • A 3-year average of $820229.8 and a median of $816584.0 in 2021 define the central range for Non-Current Receivables.
  • Biggest YoY gain for Non-Current Receivables was 3.3% in 2020; the steepest drop was 3.3% in 2020.
  • Vivos Therapeutics' Non-Current Receivables stood at $785061.0 in 2019, then increased by 3.3% to $811000.0 in 2020, then grew by 3.86% to $842290.0 in 2021.
  • Per Business Quant, the three most recent readings for VVOS's Non-Current Receivables are $842290.0 (Q3 2021), $846214.0 (Q2 2021), and $816584.0 (Q1 2021).